The Catalyst



The best health stems from the best information, and this includes biopharmaceutical information-sharing with physicians and patients. As the creators of many of the medicines we all rely upon, the companies have the most up to date knowledge on safety and benefit/risk, making conversations with prescribing physicians imperative to better care.

12.20.13 | By Jay Taylor

What provides two-thirds of the Trans-Pacific Partnership (TPP) agreement’s total economic benefits? The answer is intellectual property-intensive manufacturing industries.


Rather than trying to uncover what’s at play behind a woman’s struggle to pay for the costs of her leukemia medicine, last night’s ABC World News with Diane Sawyer barely scratched the surface of a complex issue. The result: a one-sided, overly simplistic view of the cost of cancer medicines in the United States.

12.17.13 | By John Castellani

When we launched Conversations in June of this year, our goal was to blend formal contributors with an ongoing opportunity for experts and thought leaders to weigh in on a broad range of high-level policy topics. The forum has been a tremendous success.

12.17.13 | By Mit Spears

Last week, I had the opportunity to participate in a panel discussion at the Elsevier Business Intelligence FDA/CMS Summit entitled, “Beyond the Label.” 


PhRMA Pushes Back on New York Times


Worth a read are the commentaries surrounding the latest Room for Debate question posed by the New York Times; it’s a good snapshot into the various views on the issue of biopharmaceutical and physician interaction.


I walked away from Friday morning’s “Research in Your Backyard:  Pharmaceutical Clinical Trials in Minnesota” breakfast meeting in Minneapolis mightily impressed with two things: Frank Jaskulke’s very maroon and gold running shoes –a great contrast with the conservative suit the Minnesota life sciences thought leader was wearing – and w


Discovering and developing new treatments for the world’s most pressing health challenges helps inspire the work of innovators across the biopharmaceutical sector. More importantly, it’s our end-goal to ensure that patients around the world can obtain such innovative treatments in a timely manner.


It’s hard to see the silver lining when it comes to cancer, as many view the disease as a devastating prognosis. And while cancer can take a serious toll on patients and their loved ones, they should know that tremendous strides are being made in the research and development of new cancer medicines that are allowing patients to lead longer, healthier lives.

12.12.13 | By Preet Bilinski

Recently the 26th Anniversary of World AIDS Day was celebrated, along with the remarkable progress that has been made against this disease.


Between Lake Champlain and the Green Mountains of Vermont, the Burlington area houses one of the economic cores of the region.  Yesterday’s "Research in Your Backyard," event brought together researchers, doctors and patients, and focused on the biopharmaceutical industry’s contributions to the state’s prosperity through


Over the weekend, the Washington Post ran a story about the price of prescription medicines offered through the Medicare Part B program, a benefit that provides coverage for outpatient administered medicines.


According to the World Health Organization (WHO), neglected tropical diseases (NTDs) affect more than 1 billion people around the world and are prevalent in more than 149 countries.


It’s a basic tenant of our industry: the well-being of patients is one of the most important pillars of the biopharmaceutical industry. Whether in the creation of new medications or updating information about current medicine, our industry strives to educate patients safely and transparently on the status of treatments that could change their lives.


Birthdays provide a great opportunity to look back and reflect on accomplishments made along the way. On December 8, 2003, the Medicare Prescription Drug, Improvement, and Modernization Act, which created Medicare Part D, was signed into law. Since its enactment 10 years ago, the program has racked up an impressive track record.


If you follow PhRMA and especially the Catalyst, you’ll notice we spend a lot of time focusing on how innovative medicines can be a great, transformative technology. A great example includes this morning’s NPR Morning Edition, reporting on new medicines to treat Hepatitis C, soon to be approved by the FDA. 


Biopharmaceutical research companies have already conducted more than 3,400 clinical trials of new medicines in Alabama since 1999.  And Governor Robert Bentley made clear yesterday his desire to see the valuable partnership between the biopharmaceutical sector and his state’s research institutions continue well into the future.

12.04.13 | By Dr. William "Bill" Chin, M.D.

Earlier this year, PhRMA member companies, along with member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA), announced new 

12.02.13 | By Mark Grayson

Fake medicines put patients and the public at risk. In the U.S. almost all fake medicines enter the drug supply through purchases over the internet. This is a pervasive problem all around the world.